Back to search results
NCT07061769

Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

Enrolling by Invitation
NAAges 18–60InterventionalTreatment
FluxWear, INC
~50 participants
Updated 2025-07-11 on ClinicalTrials.gov
What's tested:SHIFT

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decrease in Neuropathic Pain Intensity
Measured over 12 weeks
+2 more outcomes measured

Conditions

Chemotherapy Induced Peripheral Neuropathy
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Chemotherapy Induced Pain Neuropathy
Chemotherapy Induced Neuropathic Pain

Explore related trials

Chemotherapy-Induced Peripheral Neuropathy

Where it's being run

1 sites across 1 states
California1

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Able to use smart phone and willing to receive text messages/emails
Has CIPN disorder/neuropathic pain related to chemotherapy
Able and willing to follow instructions
Not participated in any other clinical study within the past two months that may influence the results of this study

Exclusion

History of seizures
Hydrocephalic
Had a change in medical therapy related to the treatment of neuropathy or chronic pain in the last fourteen days
Received repetitive transcranial magnetic stimulation (rTMS) in the last 60 days
Implanted device or metal in the brain
History of brain bleed in the last six months
History of suicidal behavior, bipolar disorder, schizophrenia
Active radiation over the scalp
Brain metastases
Currently participates in other neuropathic pain studies
Has any other medical condition that would prevent them from participating, including scalp wounds, hyperhidrosis, sensitive scalp, rash
Pregnant

What this trial measures

  • Decrease in Neuropathic Pain Intensity12 weeks

    Measured through scores in the Neuropathy Pain Scale. The Neuropathy Pain Scale uses a range a 0 to 10, with 0 being no pain/sensation and 10 being the most intense pain/sensation imaginable.

  • Decrease in Numeric Pain Rating.12 weeks

    Measured through Numeric Pain Rating surveys. The numeric pain rating scale uses a range of 0 to 10, with 0 being no pain and 10 being the worst pain possible.

  • Improvement in Neuropathic Pain Symptoms12 weeks

    Measured in weekly scores in the Neuropathic Pain Symptom Inventory. The inventory uses a scale of 1 to 10, with 1 being the no symptom and 10 being the worst symptom imaginable.